If you have been reading about IGF-1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-26. Numbers and descriptions here follow the published literature rather than marketing material.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
The peptide is supplied as a lyophilized powder in single-use vials and is normally kept refrigerated between two and eight degrees Celsius, protected from light. Once dissolved, the solution is handled carefully because peptide bonds and the acyl modification can degrade under warm or alkaline conditions. Vials are inspected for cracks, and the powder is checked for color and uniformity before handling. Temperature excursions during shipping are a frequent reason for quality questions.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | 2 to 8 °C | Refrigerated, protected from light |
| Appearance | White to off-white powder | Lyophilized cake in a single-use vial |
| Solubility | Soluble in water | Yields a clear solution after reconstitution |
| Identity method | Electrospray mass spectrometry | Confirms the expected molecular mass |
| Purity method | Reversed-phase HPLC | Reports main peak against related substances |
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
== Physiologie == Unter dem Einfluss serotoninerger und adrenerger Neuronen wird die Thyreoliberin-Biosynthese im Hypothalamus stimuliert und die Freisetzung induziert. Im Gegensatz zu anderen Releasing-Hormonen scheint Thyreoliberin nur zu einem geringen Teil unter der Feedback-Kontrolle der regulierten Hormone (T3 und T4) zu stehen. Über das hypothalamisch-hypophysäre Pfortadersystem wird TRH zum Vorderlappen der Hirnanhangsdrüse (Adenohypophyse) transportiert. Im Vorderlappen stimuliert Thyreoliberin die Bildung und die Ausschüttung von Prolaktin und dem Thyreotropin (TSH), dem sogenannten Schilddrüsen-(Thyreoidea-)stimulierenden Hormon. Über TSH stimuliert das Thyreoliberin damit auch die Ausschüttung der Schilddrüsenhormone T4 und T3 in der Schilddrüse. Die TRH-Freisetzung wird u. a. stimuliert, wenn die Körpertemperatur sinkt: Durch die dann erfolgende TSH- und anschließende T4-Freisetzung wird der Stoffwechsel stimuliert, der über einen erhöhten Zuckerstoffwechsel die Körpertemperatur wieder ansteigen lässt. Auch andere Energie-fordernde Mechanismen stimulieren die TRH-Freisetzung. TRH ist als Stimulator der TSH- und Prolaktin-Freisetzung ein Neuropeptid-Hormon. Andererseits wirkt es auch als Neurotransmitter in Hirnregionen außerhalb des Hypothalamus sowie in Pankreas und Schilddrüse. Unter dem Einfluss des Nucleus suprachiasmaticus erfolgt die TRH-Freisetzung in einem cirkadianen Rhythmus mit maximaler Freisetzung etwa um Mitternacht und minimaler Freisetzung am späten Nachmittag.
Ultradiane Sekretionsspitzen wurden zusätzlich in einem Abstand von 2 bis 4 Stunden beobachtet. Die rhythmische TRH-Freisetzung wird außerdem durch das limbische System, die Zirbeldrüse und weitere Hirnregionen, wichtig für die Stress-Antwort, beeinflusst. Liegt ein Defekt am Vorderlappen der Hirnanhangsdrüse (Hypophysenvorderlappeninsuffizienz) vor, so dass der Vorderlappen der Hirnanhangsdrüse nicht mehr oder nur noch vermindert auf das Thyreoliberin reagiert, so schüttet der Vorderlappen der Hirnanhangsdrüse, trotz ausreichender Thyreoliberinversorgung, zu wenig oder kein TSH aus, was wiederum zu einer verminderten Herstellung und Ausschüttung von T4 und T3 führt. Es entsteht eine sogenannte sekundäre Hypothyreose. Ist die Versorgung des Vorderlappens mit Thyreoliberin gestört, so hat dies dieselben Folgen wie die eben beschriebene verminderte Reaktivität des Hypophysenvorderlappens; dies bezeichnet man aber aufgrund des anders gearteten Entstehungsmechanismus als tertiäre Hypothyreose. Sie entsteht z. B. bei einer Unterbrechung des Portalgefäßsystems zwischen Hypothalamus und Hypophyse (Pickardt-Syndrom). Neben seiner Hauptwirkung auf die Hypophyse stimuliert Thyreoliberin auch die Freisetzung von Prolaktin, einem Hormon, welches die Milchproduktion der weiblichen Brust anregt. Bei Patienten mit Akromegalie oder Riesenwuchs kommt es in etwa der Hälfte der Fälle nach TRH-Gabe zu einem Anstieg der Wachstumshormon-Sekretion. Bei gesunden Personen wird dies nicht beobachtet. Die Halbwertszeit liegt bei etwa zwei Minuten.
=== Zentralnervöse Wirkungen === Ein größerer Teil des Thyreoliberins hat eine direkte Wirkung im Gehirn, die nichts mit der Wirkung im Schilddrüsenregelkreis zu tun hat. So erklärt sich auch die geringe bremsende Wirkung eines erhöhten Blutspiegels von T3 und T4 auf den TRH-Spiegel. Thyreoliberin ist als Neurotransmitter im Gehirn
an der Thermoregulation, an der Schmerzunterdrückung, an der Schlaf-Wach-Regulation, an der Bremsung von Nahrungs- und Flüssigkeitsaufnahme und an einer Vielzahl weiterer Steuerungsvorgänge beteiligt. Thyreoliberin hat auch indirekte vegetative Wirkungen:
Sources: de.wikipedia.org
Lyophilized material is typically kept refrigerated and away from light in the sealed vial provided. Dissolved material is generally used within a limited period rather than stored long term.
Mass spectrometry gives the molecular weight, and mapping after digestion gives sequence coverage. Reversed-phase chromatography then supplies a purity profile.
Different groups report purity with different methods and thresholds, and full validation data are seldom published. Direct comparison of activity across batches therefore stays uncertain.
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.